Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic

키워드

참고문헌 (154)

1. Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
2. "WHO announces COVID-19outbreak a pandemic" (2020)[URL]
3. "Coronavirus disease (COVID-19) pandemic" (2020)[URL]
4. Jin Yong Kim, "The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures", Journal of Korean Medical Science, 35(5), pp.1~4 (2020), 대한의학회[DOI]
5. Ceribelli A, "Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy", J Autoimmun, 109, pp.102442~ (2020)
6. Au K, "High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis", Ann Rheum Dis, 70, pp.785~791 (2011)
7. Franklin J, "Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis", Ann Rheum Dis, 66, pp.308~312 (2007)
8. Lacaille D, "Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis", Arthritis Rheum, 59, pp.1074~1081 (2008)
9. Jani M, "Prediction of infection risk in rheumatoid arthritis patients treated with biologics : are we any closer to risk stratification", Curr Opin Rheumatol, 31, pp.285~292 (2019)
10. Youssef J, "Infection risk and safety of corticosteroid use", Rheum Dis Clin North Am, 42, pp.157~176 (2016)
11. Gabriel SE, "Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases", Arthritis Res Ther, 11, pp.229~ (2009)
12. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
13. Ruan Q, "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China", Intensive Care Med, 46, pp.846~848 (2020)
14. "OCEBM levels of evidence" (2016)[URL]
15. "The RAND/UCLA appropriateness method user’s manual" (2001)[URL]
16. Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
17. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
18. Wang D, "Clinical characteristics of 138hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
19. Wu Z, "Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19)outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
20. "EULAR calls on governments in Europe to recognize the most vulnerable during COVID-19" (2020)[URL]
21. "People who are at increased risk for severe illness" (2020)[URL]
22. Feng Y, "COVID-19 with different severities:a multicenter study of clinical features", Am J Respir Crit Care Med, 201, pp.1380~1388 (2020)
23. Gluck T, "Immune status and risk for infection in patients receiving chronic immunosuppressive therapy", J Rheumatol, 32, pp.1473~1480 (2005)
24. Salliot C, "Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients", Rheumatology (Oxford), 46, pp.327~334 (2007)
25. Listing J, "The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment", Rheumatology(Oxford), 52, pp.53~61 (2013)
26. Singh JA, "Infections with biologics in rheumatoid arthritis and related conditions : a scoping review of serious or hospitalized infections in observational studies", Curr Rheumatol Rep, 18, pp.61~ (2016)
27. Pappas DA, "Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs", Arthritis Care Res(Hoboken), 67, pp.1671~1678 (2015)
28. Bechman K, "A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis", Rheumatology(Oxford), 58, pp.1755~1766 (2019)
29. "Korean Society of Infectious Diseases recommendations for COVID-19" (2020)[URL]
30. "Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases:interim guidance, 2 March 2020" (2020)[URL]
31. "Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020" (2020)[URL]
32. "Overview of testing for SARS-CoV-2" (2020)[URL]
33. Gianfrancesco MA, "Rheumatic disease and COVID-19 : initial data from the COVID-19Global Rheumatology Alliance provider registries", Lancet Rheumatol, 2, pp.e250~e253 (2020)
34. Misra DP, "Rheumatologists’perspective on coronavirus disease 19(COVID-19)and potential therapeutic targets", Clin Rheumatol, 39, pp.2055~2062 (2020)
35. Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update", Ann Rheum Dis, 79, pp.685~699 (2020)
36. Van der Heijde D, "2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis", Ann Rheum Dis, 76, pp.978~991 (2017)
37. Smolen JS, "Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force", Ann Rheum Dis, 77, pp.3~17 (2018)
38. Fanouriakis A, "2019 uUpdate of the EULAR recommendations for the management of systemic lupus erythematosus", Ann Rheum Dis, 78, pp.736~745 (2019)
39. "Clinical management of severe acute respiratory infection (SARI) when COVID-19disease is suspected: interim guidance, 13 March 2020" (2020)[URL]
40. "Coronavirus guidance for clinicians and NHS" (2020)[URL]
41. "Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19)" (2020)[URL]
42. "Coronavirus disease 2019(COVID-19) treatment guidelines" (2020)[URL]
43. "Clinical management of COVID-19: interim guidance, 27 May 2020" (2020)[URL]
44. "Interim recommendations on obligatory hand hygiene against transmission of COVID-19" (2020)[URL]
45. Jefferson T, "Physical interventions to interrupt or reduce the spread of respiratory viruses", Cochrane Database Syst Rev, 2011, pp.CD006207~ (2011)
46. "Hand disinfectant and COVID-19" (2020)[URL]
47. "Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1. Face masks, eye protection and person distancing: systematic review and meta-analysis"[URL]
48. Feng S, "Rational use of face masks in the COVID-19 pandemic", Lancet Respir Med, 8, pp.434~436 (2020)
49. Bae S, "Effectiveness of surgical and cotton masks in blocking SARS-CoV-2 : a controlled comparison in 4 patients", Ann Intern Med, 173, pp.W22~W23 (2020)
50. Leung NH, "Respiratory virus shedding in exhaled breath and efficacy of face masks", Nat Med, 26, pp.676~680 (2020)
51. "Face masks against COVID-19: an evidence review" (2020)[URL]
52. Greenhalgh T, "Face masks for the public during the covid-19 crisis", BMJ, 369, pp.m1435~ (2020)
53. "What is the evidence for social distancing during global pandemics?" (2020)[URL]
54. 최선화, "Estimating the reproductive number and the outbreak size of COVID-19 in Korea", Epidemiology and Health, 42, pp.1~10 (2020), 한국역학회[DOI]
55. "Preventive measures against COVID-19" (2020)[URL]
56. "Social distancing" (2020)[URL]
57. "Coronavirus disease(COVID-19) advice for the public" (2020)[URL]
58. "How to protect yourself & others" (2020)[URL]
59. "Social distancing: what you need to do" (2020)[URL]
60. Sveaas SH, "Effect of cardiorespiratory and strength exercises on disease activity in patients with inflammatory rheumatic diseases : a systematic review and meta-analysis", Br J Sports Med, 51, pp.1065~1072 (2017)
61. Agca R, "EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015", 2016 update, 2017, pp.76, 17~28
62. Rausch Osthoff AK, "2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis", Ann Rheum Dis, 77, pp.1251~1260 (2018)
63. Garber CE, "American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults : guidance for prescribing exercise", Med Sci Sports Exerc, 43, pp.1334~1359 (2011)
64. Ahmadinejad Z, "Common sports-related infections : a review on clinical pictures, management and time to return to sports", Asian J Sports Med, 5, pp.1~9 (2014)
65. Halabchi F, "COVID-19epidemic: exercise or not to exercise; that is the question!", Asian J Sports Med, 11, pp.e102630~ (2020)
66. "Q&A: be active during COVID-19" (2020)[URL]
67. "Smoking in acute respiratory infections" (2020)[URL]
68. "Tobacco and waterpipe use increases the risk of COVID-19" (2020)[URL]
69. Vardavas CI, "COVID-19 and smoking : a systematic review of the evidence", Tob Induc Dis, 18, pp.20~ (2020)
70. Berlin I, "COVID-19 and smoking", Nicotine Tob Res, 22, pp.1650~1652 (2020)
71. Freund KM, "The health risks of smoking : the Framingham Study : 34 years of follow-up", Ann Epidemiol, 3, pp.417~424 (1993)
72. Will JC, "Cigarette smoking and diabetes mellitus : evidence of a positive association from a large prospective cohort study", Int J Epidemiol, 30, pp.540~546 (2001)
73. Komiyama M, "Smoking cessation as a public health measure to limit the coronavirus disease 2019 pandemic", Eur Cardiol, 15, pp.e16~ (2020)
74. Sopori M, "Effects of cigarette smoke on the immune system", Nat Rev Immunol, 2, pp.372~377 (2002)
75. Sugiyama D, "Impact of smoking as a risk factor for developing rheumatoid arthritis : a meta-analysis of observational studies", Ann Rheum Dis, 69, pp.70~81 (2010)
76. Formica MK, "Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women’s Health Study", J Rheumatol, 30, pp.1222~1226 (2003)
77. Chasset F, "Influence of smoking on the efficacy of antimalarials in cutaneous lupus : a meta-analysis of the literature", J Am Acad Dermatol, 72, pp.634~639 (2015)
78. Piette EW, "Impact of smoking in cutaneous lupus erythematosus", Arch Dermatol, 148, pp.317~322 (2012)
79. Tam LS, "2018 APLAR axial spondyloarthritis treatment recommendations", Int J Rheum Dis, 22, pp.340~356 (2019)
80. Kim D, "Rates of co-infection between SARS-CoV-2 and other respiratory pathogens", JAMA, 323, pp.2085~2086 (2020)
81. Wu X, "Co-infection with SARS-CoV-2and influenza A virus in patient with pneumonia, China", Emerg Infect Dis, 26, pp.1324~1326 (2020)
82. Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
83. Cox MJ, "Co-infections : potentially lethal and unexplored in COVID-19", Lancet Microbe, 1, pp.e11~ (2020)
84. "Correlation of influenza vaccination and influenza incidence on COVID-19 severity" (2020)[URL]
85. Furer V, "2019 Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases", Ann Rheum Dis, 79, pp.39~52 (2020)
86. O’Mahony R, "Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis : a systematic review and meta-analysis", Ann Rheum Dis, 69, pp.1823~1826 (2010)
87. Galvao TF, "Withdrawal of biologic agents in rheumatoid arthritis : a systematic review and meta-analysis", Clin Rheumatol, 35, pp.1659~1668 (2016)
88. LaRochelle GE Jr, "Recovery of the hypothalamic-pituitary-adrenal(HPA)axis in patients with rheumatic diseases receiving lowdose prednisone", Am J Med, 95, pp.258~264 (1993)
89. Joseph RM, "Systemic glucocorticoid therapy and adrenal insufficiency in adults : a systematic review", Semin Arthritis Rheum, 46, pp.133~141 (2016)
90. Hoes JN, "EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases", Ann Rheum Dis, 66, pp.1560~1567 (2007)
91. Voiriot G, "Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients", J Clin Med, 8, pp.786~ (2019)
92. Day M, "Covid-19 : ibuprofen should not be used for managing symptoms, say doctors and scientists", BMJ, 368, pp.m1086~ (2020)
93. "COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders" (2020)[URL]
94. Torjesen I, "Covid-19 : NICE advises against using NSAIDs for fever in patients with suspected cases", BMJ, 369, pp.m1409~ (2020)
95. Little P, "Non-steroidal anti-inflammatory drugs and covid-19", BMJ, 368, pp.m1185~ (2020)
96. Torjesen I, "Covid-19 : ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear", BMJ, 369, pp.m1555~ (2020)
97. "The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19" (2020)[URL]
98. "EMA advice on the use of NSAIDs for Covid-19", Drug Ther Bull, 58, pp.69~ (2020)
99. Alessandro Giollo, "Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)", Annals of the Rheumatic Diseases, 80(2), pp.e12~e12 (2021), BMJ[DOI]
100. Chen D, "Herpes zoster in patients with systemic lupus erythematosus : clinical features, complications and risk factors", Exp Ther Med, 14, pp.6222~6228 (2017)
101. Kim SH, "Corticosteroid treatment in critically ill patients with pandemic influenza A", H1N12009 infection : analytic strategy using propensity scores, 2011, pp.183, 1207~1214
102. Hui DS, "Systemic corticosteroid therapy may delay viral clearance in patients with middle east respiratory syndrome coronavirus infection", Am J Respir Crit Care Med, 197, pp.700~701 (2018)
103. Russell CD, "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury", Lancet, 395, pp.473~475 (2020)
104. Singh AK, "Role of corticosteroid in the management of COVID-19 : a systemic review and a clinician’s perspective", Diabetes Metab Syndr, 14, pp.971~978 (2020)
105. Yushu Wang, "The influence of corticosteroid on patients with COVID-19 infection: A meta-analysis", The American Journal of Emergency Medicine (2020), Elsevier BV[DOI]
106. Mehta B, "Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases : a US national cohort study", RMD Open, 5, pp.e000935~ (2019)
107. Blumentals WA, "Rheumatoid arthritis and the incidence of influenza and influenza-related complications : a retrospective cohort study", BMC Musculoskelet Disord, 13, pp.158~ (2012)
108. Ledingham J, "BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs", Rheumatology(Oxford), 56, pp.865~868 (2017)
109. Liang W, "Cancer patients in SARSCoV-2 infection : a nationwide analysis in China", Lancet Oncol, 21, pp.335~337 (2020)
110. Zhang L, "Clinical characteristics of COVID-19-infected cancer patients : a retrospective case study in three hospitals within Wuhan, China", Ann Oncol, 31, pp.894~901 (2020)
111. Singh JA, "2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis", Arthritis Care Res(Hoboken), 68, pp.1~25 (2016)
112. Gossec L, "EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies : 2019 update", Ann Rheum Dis, 79, pp.700~712 (2020)
113. Boyman O, "Adverse reactions to biologic agents and their medical management", Nat Rev Rheumatol, 10, pp.612~627 (2014)
114. Singh JA, "Risk of serious infection in biological treatment of patients with rheumatoid arthritis : a systematic review and meta-analysis", Lancet, 386, pp.258~265 (2015)
115. Strangfeld A, "Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents", JAMA, 301, pp.737~744 (2009)
116. Winthrop KL, "Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster", JAMA, 309, pp.887~895 (2013)
117. Luo P, "Tocilizumab treatment in COVID-19 : a single center experience", J Med Virol, 92, pp.814~818 (2020)
118. Michot JM, "Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure : a case report", Ann Oncol, 31, pp.961~964 (2020)
119. Zhang C, "Cytokine release syndrome in severe COVID-19 : interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality", Int J Antimicrob Agents, 55, pp.105954~ (2020)
120. Xu X, "Effective treatment of severe COVID-19 patients with tocilizumab", Proc Natl Acad Sci U S A, 117, pp.10970~10975 (2020)
121. Buonaguro FM, "Anti-IL6R role in treatment of COVID-19-related ARDS", J Transl Med, 18, pp.165~ (2020)
122. Fu B, "Why tocilizumab could be an effective treatment for severe COVID-19", J Transl Med, 18, pp.164~ (2020)
123. Nicastri E, "National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS:recommendations for COVID-19 clinical management", Infect Dis Rep, 12, pp.8543~ (2020)
124. Richardson P, "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease", Lancet, 395, pp.e30~e31 (2020)
125. Richardson PJ, "Baricitinib for COVID-19 : a suitable treatment? : authors’ reply", Lancet Infect Dis, 20, pp.1013~1014 (2020)
126. Favalli EG, "Baricitinib for COVID-19 : a suitable treatment", Lancet Infect Dis, 20, pp.1012~1013 (2020)
127. Zhang W, "The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019(COVID-19) : the perspectives of clinical immunologists from China", Clin Immunol, 214, pp.108393~ (2020)
128. Russell B, "Associations between immune-suppressive and stimulating drugs and novel COVID-19 : a systematic review of current evidence", Ecancermedicalscience, 14, pp.1022~ (2020)
129. Praveen D, "Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19", Int J Antimicrob Agents, 55, pp.105967~ (2020)
130. Pawar A, "Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis : a multidatabase cohort study", Lancet Rheumatol, 2, pp.e84~e98 (2020)
131. Favalli EG, "Tofacitinib’s infectious profile : concerns for clinical practice", Lancet Rheumatol, 2, pp.e65~e67 (2020)
132. Anderson DM, "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", Nature, 390, pp.175~179 (1997)
133. Padigel UM, "TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice", J Immunol, 171, pp.5437~5441 (2003)
134. Barbaroux JB, "Epidermal receptor activator of NF-kappaB ligand controls Langerhans cells numbers and proliferation", J Immunol, 181, pp.1103~1108 (2008)
135. Loser K, "Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells", Nat Med, 12, pp.1372~1379 (2006)
136. Cummings SR, "Denosumab for prevention of fractures in postmenopausal women with osteoporosis", N Engl J Med, 361, pp.756~765 (2009)
137. Wensel TM, "Effects of denosumab on bone mineral density and bone turnover in postmenopausal women", Pharmacotherapy, 31, pp.510~523 (2011)
138. Miller PD, "Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy : a randomized blinded phase 2 clinical trial", Bone, 43, pp.222~229 (2008)
139. Cummings SR, "Vertebral fractures after discontinuation of denosumab : a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension", J Bone Miner Res, 33, pp.190~198 (2018)
140. Anastasilakis AD, "Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation : systematic review and additional cases", J Bone Miner Res, 32, pp.1291~1296 (2017)
141. Lamy O, "Severe rebound-associated vertebral fractures after denosumab discontinuation : 9 clinical cases report", J Clin Endocrinol Metab, 102, pp.354~358 (2017)
142. Doran MF, "Frequency of infection in patients with rheumatoid arthritis compared with controls : a population-based study", Arthritis Rheum, 46, pp.2287~2293 (2002)
143. Doaty S, "Infection and lupus : which causes which", Curr Rheumatol Rep, 18, pp.13~ (2016)
144. Zandman-Goddard G, "Infections and SLE", Autoimmunity, 38, pp.473~485 (2005)
145. Koetz K, "T cell homeostasis in patients with rheumatoid arthritis", Proc Natl Acad Sci U S A, 97, pp.9203~9208 (2000)
146. Fessler J, "Premature senescence of T-cell subsets in axial spondyloarthritis", Ann Rheum Dis, 75, pp.748~754 (2016)
147. Segal BH, "Infectious complications of immunosuppressive therapy in patients with rheumatic diseases", Rheum Dis Clin North Am, 23, pp.219~237 (1997)
148. Zhang X, "Viral and host factors related to the clinical outcome of COVID-19", Nature, 583, pp.437~440 (2020)
149. Gianfrancesco M, "Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease : data from the COVID-19Global Rheumatology Alliance physician-reported registry", Ann Rheum Dis, 79, pp.859~866 (2020)
150. Williamson EJ, "Factors associated with COVID-19-related death using OpenSAFELY", Nature, 584, pp.430~436 (2020)
151. Pablos JL, "Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases", Ann Rheum Dis, 79, pp.1170~1173 (2020)
152. "Testing early, testing late: four countries’ approaches to COVID-19 testing compared" (2020)[URL]
153. Peck KR, "Early diagnosis and rapid isolation : response to COVID-19 outbreak in Korea", Clin Microbiol Infect, 26, pp.805~807 (2020)
154. Chu DK, "Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis", Lancet, 395, pp.1973~1987 (2020)

관련 논문AI추천